Skip to main content

Drug Interactions between AccessPak for HIV PEP Expanded with Viracept and delavirdine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nelfinavir delavirdine

Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil) and delavirdine

MONITOR: Coadministration with delavirdine may significantly increase the plasma concentrations of nelfinavir. The mechanism is delavirdine inhibition of nelfinavir metabolism via CYP450 3A4 and 2C19. According to the delavirdine labeling, coadministration of delavirdine (400 mg three times a day) and nelfinavir (750 mg three times a day) for 7 days increased the mean peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough plasma concentration (Cmin) of nelfinavir by 88%, 107% and 136%, respectively, compared to administration of nelfinavir alone. Plasma concentrations of the active metabolite, nelfinavir hydroxy-t-butylamide, were significantly reduced but were more than compensated for by the increased nelfinavir concentration. Delavirdine Cmax, AUC and Cmin decreased by 27%, 31% and 33%, respectively.

MANAGEMENT: Appropriate dosages for the combination of nelfinavir and delavirdine with respect to safety and efficacy have not been established. Patients should be monitored for toxicity such as elevations in liver function tests, neutropenia, and undue gastrointestinal disturbances, especially diarrhea.

References (2)
  1. (2001) "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn
  2. Developed by the panel of Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) (2004) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSinfo.nih.gov

Drug and food interactions

Minor

tenofovir food

Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil)

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References (1)
  1. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer